Orforglipron UK: The New GLP-1 Weight Loss Pill

Published on: June 3, 2026

Medically reviewed by

Ashis Tandukar

Superintendent Pharmacist · Reg: GPhC No. 2084170

For years the catch with the most effective weight loss medicines has been the needle. Mounjaro and Wegovy work brilliantly for a lot of people, but a weekly injection is a real barrier for some — whether that's a genuine fear of needles or simply not fancying the ritual. So the arrival of a GLP-1 that comes as a daily tablet has understandably got people's attention.

That tablet is orforglipron, sold in the United States under the brand name Foundayo. You may have seen the headlines. What's harder to find is a calm, honest account of what it actually does, how it stacks up against the injections, and — the question we get asked most — whether you can actually get it in the UK yet. Let's go through it properly.

What is orforglipron?

Orforglipron is a GLP-1 receptor agonist — the same broad family as Wegovy (semaglutide) and the GLP-1 side of Mounjaro (tirzepatide). It mimics a gut hormone called GLP-1, which quietens appetite, slows how fast your stomach empties, and helps steady blood sugar. The practical upshot is the one most people care about: you feel full sooner, stay full for longer, and the constant pull towards food eases off.

The difference is in the chemistry. Semaglutide and tirzepatide are large peptide molecules that your gut would break down if you swallowed them, which is why they're injected. Orforglipron is a small molecule, built to survive digestion — so it works as a plain daily tablet. It's made by Eli Lilly, the same company behind Mounjaro, though it's worth saying clearly: orforglipron is not a tablet version of Mounjaro. Mounjaro works on two hormone receptors (GIP and GLP-1); orforglipron works on one.

Is orforglipron available in the UK?

This is the part that matters most, so here it is without any hedging: no. As of mid-2026, orforglipron is not approved or available in the UK.

It was approved in the United States by the FDA in April 2026, under the brand name Foundayo, for weight management and type 2 diabetes. Eli Lilly has submitted it to regulators in dozens of countries, and the UK's medicines regulator, the MHRA, would need to authorise it before it could be prescribed here. After that, NICE would assess whether it should be funded on the NHS — a separate step that has its own appraisal already in progress. If both go smoothly, a private prescription route would likely come first, with NHS access later, as we've seen with every other GLP-1.

There's no confirmed UK launch date. Anyone promising otherwise is guessing.

How well does orforglipron work?

The headline figure comes from the phase 3 ATTAIN trial programme, which tested orforglipron in thousands of people with obesity or excess weight. At the highest dose, people lost an average of around 11% of their body weight over 72 weeks, compared with roughly 2% for those on a placebo.

Digging into that average is more useful than the number alone. In the trial, just over half of people on the top dose lost at least 10% of their starting weight, around a third lost 15% or more, and close to one in five lost 20% or more. Alongside the weight, there were improvements in things that matter for long-term health — waist size, cholesterol, and blood pressure.

It's an effective medicine. It's also, on the current evidence, somewhat less powerful than the best injections — and being upfront about that is the honest way to frame it.

Orforglipron vs Mounjaro and Wegovy

Here's roughly how the main options compare, based on their headline trial results. A quick caveat before the table: these come from separate trials of different lengths, so it's a guide to the general picture rather than a head-to-head race.

The pattern is fairly clear. If raw effectiveness is your only measure, the injections — especially Mounjaro — still lead. Our guide comparing Wegovy and Mounjaro goes into that choice in detail.

But effectiveness isn't the only thing that decides whether a treatment works for a real person. A medicine you'll actually take, week in and week out, beats a slightly stronger one you dread or abandon. For someone who won't inject — or keeps meaning to start an injection and never quite does — an effective daily pill could be the option that finally fits. There's also the simple convenience: orforglipron can be taken at any time of day, with or without food, which isn't true of the existing oral semaglutide tablet.

What are the side effects of orforglipron?

If you know anyone on a GLP-1, the list will look familiar. The most common side effects in trials were digestive: nausea, vomiting, diarrhoea and constipation. They were mostly mild to moderate, tended to show up early or after a dose increase, and settled with time — the same rhythm seen across this whole class of medicines.

Nausea was the most frequently reported, affecting somewhere between roughly one in eight and one in three people depending on the dose and how quickly it was increased. As with the injections, starting low and going up slowly is what keeps side effects manageable. Overall, the safety picture in trials looked broadly in line with injectable GLP-1 medicines rather than worse.

One honest limitation: orforglipron is new. The injectable GLP-1s now have years of real-world use behind them, and orforglipron simply doesn't yet — so the long-term, large-population picture is still being filled in. That's not a reason for alarm, but it is a reason for the usual caution that comes with any newly approved medicine. If you'd like the wider safety context for this class, our evidence-based look at GLP-1 safety is a good companion read.

How is orforglipron taken?

The appeal in one line: a single tablet a day, swallowed whenever suits you, no need to time it around meals or water. That flexibility is genuinely different from the existing oral semaglutide tablet, which has to be taken on an empty stomach with strict timing.

Like every GLP-1, it's started at a low dose and increased gradually — in the US, roughly once a month — to let your body adjust and to keep nausea in check. And like every GLP-1, it isn't a standalone fix. It works alongside eating well and moving more, not instead of them. The medicine makes those changes easier to sustain by taking the edge off appetite; it doesn't do the whole job by itself.

So is it worth waiting for?

For some people, yes — particularly anyone who has ruled out treatment purely because of the injection. For others, waiting for a medicine with no confirmed UK date, when effective options are already here, may not make sense. There's no single right answer, and it depends on what's been holding you back.

It's also worth remembering orforglipron isn't the only thing in the pipeline. The field is moving quickly, with other new treatments like retatrutide in development too. If you want the current lay of the land, our overview of weight loss medication in the UK covers what's actually available to you now.

A quick note on cost

UK pricing is unknown, because the medicine isn't licensed here and no price has been set. In the United States, Foundayo launched at somewhere around $149 to $349 a month depending on dose and how you pay. UK pricing will depend on MHRA approval, what Lilly sets, and — for any NHS access — NICE's verdict. Until all of that lands, any UK figure you see quoted is speculation. If you're weighing up what's available now, our rundown of weight loss pills in the UK is a more useful place to start.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.